Lawsuit Claims Birth Control Packaging Error Led to More Than 100 Unwanted Pregnancies The suit seeks millions in damages including, in some cases, child-rearing expenses up to the age of 18.

By Laura Entis

Opinions expressed by Entrepreneur contributors are their own.

Shutterstock

In 2011, Qualitest Pharmaceuticals recalled 1.4 million packages of birth control pills due to a packaging error that reversed the weekly tablet order. Instead of appearing at the bottom of the package, the placebo pills, which are meant to be taken the week of menstruation, were flipped 180 degrees. To be effective, birth control pills must be taken in the proper order.

Now, more than 100 women are suing Qualitest, claiming that the incorrect packaging resulted in unwanted pregnancies. All but four of the 113 women involved became pregnant, and more than 90 gave birth, the Associated Press reports.

Related: Amazon Sues More Than 1,000 People Over Fake Reviews

The suit seeks millions in damages, including recovery for medical expenses, pain and suffering, lost wages and, in some cases, child-rearing expenses up to the age of 18.

The lawsuit was filed this week in Pennsylvania, where Qualitest's parent company Endo Pharmaceuticals is headquartered, directly after a federal judge in Georgia denied class-action certification to a similar suit filed in the state. Vintage Pharmaceuticals and Patheon were also named in the suit.

In a statement to ABC News, Endo Pharmaceuticals said that it had only been able to confirm one defected birth control pack that was sold to a patient.

Endo's statement, in full:

Our commitment is to patient safety and we take product quality very seriously. ... There is no new or recent product recall. The recall that forms the basis of this suit was entirely voluntary and occurred more than four years ago in September 2011. The voluntary recall occurred based on an extremely small number of pill packs that were manufactured by an external contract manufacturer. Endo has been able to confirm only one blister pack that manifested a defect and was sold to a patient. Additionally, courts have dismissed cases arising out of the recall because the plaintiff could not establish that she purchased a defective package.

The FDA's 2011 recall included the following oral contraceptives: Cyclafem 7/7/7, Cyclafem 1/35, Emoquette, Gildess FE 1.5/30, Gildess FE 1/20, Orsythia, Previfem and Tri-Previfem.

Related: Drone Owners Will Soon Have to Register With the Federal Government

Laura Entis is a reporter for Fortune.com's Venture section.

Want to be an Entrepreneur Leadership Network contributor? Apply now to join.

Editor's Pick

Business News

JPMorgan Shuts Down Internal Message Board Comments After Employees React to Return-to-Office Mandate

Employees were given the option to leave comments about the RTO mandate with their first and last names on display — and they did not hold back.

Business Ideas

70 Small Business Ideas to Start in 2025

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2025.

Business News

'More Soul-Crushing Than Ever': Popular Hiring Platform Finds Around 20% of Its Postings Were 'Ghost Jobs'

Is that job listing too good to be true? There's a one-in-five chance that it might be.

Business News

'Masculine Energy Is Good': Mark Zuckerberg Tells Joe Rogan He Thinks Companies Need More Aggression

On the most recent episode of "The Joe Rogan Experience," Meta CEO Mark Zuckerberg said corporate culture has become "neutered."

Business News

Zillow Predicts These 10 Places Will Have the Hottest Housing Markets in 2025

Zillow predicted that the hottest housing market of 2025 will be Buffalo, New York. Here's why.

Growing a Business

5 Risk-Taking Lessons From Founders Who Bet Big and Won

Discover the bold moves and strategic risks that catapulted these entrepreneurs to success. Learn how their fearless decisions can inspire your own path to growth.